CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 161 enrolled
Drug / intervention
PA21drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01833494
NCT01833494Phase 3Completed
CompareCT.gov

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Kissei Pharmaceutical Co., Ltd.·interventional·Posted Apr 17, 2013·Updated Oct 9, 2018

In Brief

A Phase 3 clinical trial evaluating PA21 for Hemodialysis Patients With Hyperphosphatemia. Completed, enrolled 161 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemodialysis Patients With Hyperphosphatemia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 17, 2013
Enrollment StartMar 18, 2013
Primary CompletionAug 1, 2014
Study CompletionAug 4, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.2 years ago

Interventions

PA21drug